Novo Nordisk A/S (NYSE:NVO) Shares Bought by Focus Financial Network Inc.

Focus Financial Network Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 9.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,870 shares of the company’s stock after acquiring an additional 750 shares during the period. Focus Financial Network Inc.’s holdings in Novo Nordisk A/S were worth $763,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of NVO. Sapient Capital LLC increased its stake in shares of Novo Nordisk A/S by 1.8% in the fourth quarter. Sapient Capital LLC now owns 651,855 shares of the company’s stock valued at $56,073,000 after purchasing an additional 11,576 shares during the period. Principle Wealth Partners LLC grew its holdings in Novo Nordisk A/S by 12.8% in the 4th quarter. Principle Wealth Partners LLC now owns 4,502 shares of the company’s stock worth $387,000 after buying an additional 510 shares in the last quarter. Bristlecone Advisors LLC increased its position in Novo Nordisk A/S by 24.2% in the 4th quarter. Bristlecone Advisors LLC now owns 12,293 shares of the company’s stock valued at $1,057,000 after acquiring an additional 2,395 shares during the period. Opal Wealth Advisors LLC raised its stake in Novo Nordisk A/S by 30.3% during the 4th quarter. Opal Wealth Advisors LLC now owns 4,133 shares of the company’s stock valued at $356,000 after acquiring an additional 962 shares in the last quarter. Finally, Elevate Capital Advisors LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth $1,133,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday. They issued an “equal weight” rating on the stock. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $81.78 on Thursday. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $366.99 billion, a PE ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45. The stock’s fifty day simple moving average is $90.45 and its 200 day simple moving average is $110.60.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.